Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally.
The last earnings update was 48 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Allena Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Allena Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Allena Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Allena Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Allena Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Allena Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Allena Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Allena Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Allena Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 6.5x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Louis Brenner, also known as Lou, M.D., M.B.A., served as the Chief Operating Officer of Allena Pharmaceuticals, Inc. since April 2015 until January 2019 and has been its President since February 2017. Dr. Brenner serves as Chief Executive Officer at Allena Pharmaceuticals, Inc since January 2019. Dr. Brenner served as the Chief Medical Officer and Senior Vice President of Idera Pharmaceuticals, Inc. from January 9, 2014 to April 3, 2015. Dr. Brenner served as the Chief Medical Officer and Senior Vice President of Radius Health, Inc. from November 1, 2011 to January 2, 2014 and November 2011 to January 2, 2014. Dr. Brenner served as Senior Vice President of AMAG Pharmaceuticals, Inc. (formerly, Advanced Magnetics Inc.) from September 11, 2006 to December 2010 and served as its Chief Medical Officer. He was responsible for the success of the Advanced Magnetics's ferumoxytol program, including all aspects of the submission of the New Drug Application for ferumoxytol as an intravenous iron replacement therapeutic for the treatment of anemia in dialysis-dependent (DD) and non-dialysis dependent (NDD) chronic kidney disease patients (CKD) along with the planning and execution of subsequent indications for ferumoxytol. He is also responsible for building the Medical Affairs group at Advanced Magnetics. From June 2002 to September 2006, Dr. Brenner served in progressively senior roles at Genzyme Corporation, a biotechnology company. He served as Senior Director of Business Development for the Renal and Transplantation Units of Genzyme Corporation. He has more than a decade of industry leadership experience, including pharmaceutical development strategy, regulatory affairs, business development and marketing. His drug development successes include managing the late-stage development and regulatory submission for Feraheme® (ferumoxytol) injection in patients with chronic kidney disease (CKD) at AMAG Pharma; leading the conduct of the global Phase 3 program of a novel candidate for the treatment of osteoporosis at Radius Health; and directing global commercial planning for Renvela® (sevelamer carbonate) in patients with end stage renal disease at Genzyme. He serves as the Chairman of the Board of the National Kidney Foundation serving New England. He has been Director of Goldfinch Biopharma Inc. since February 9, 2017. He served as a Director of PLC Medical Systems, Inc. He served as Director of PLC Systems Inc. from June 2009 to June 15, 2010. He completed his residency in internal medicine at Brigham and Women’s Hospital (BWH) and his fellowship in nephrology at BWH and Massachusetts General Hospital. He is Board Certified in Nephrology and Internal Medicine and cares for patients with kidney disease at Brigham and Women's Hospital in Boston. He has published on a variety of Nephrology topics in leading scientific journals. Dr. Brenner holds a clinical appointment at BWH. Dr. Brenner holds a B.S. in Biology from Yale University, an M.D. from Duke University and an M.B.A. from the Harvard Business School.
Lou's compensation has increased whilst company is loss making.
Lou's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Allena Pharmaceuticals management team is about average.
Co-Founder & Chairman of the Board
CEO & President
CFO and VP of Finance & Administration
Co-Founder & Strategic Adviser
Senior Vice President of Technical Operations
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Allena Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.